• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Hervé Hoppenot - Articles and news items

Bristol Myers Squibb logo

Bristol-Myers Squibb and Incyte enter clinical collaboration agreement to evaluate combination regimen of two novel immunotherapies

Industry news / 28 May 2014 / Bristol-Myers Squibb Company

Bristol-Myers Squibb Company and Incyte Corporation announced the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen…

Novartis logo

Hervé Hoppenot, President of Novartis Oncology, leaves Novartis to pursue career opportunity outside of organization

Industry news / 12 January 2014 / Novartis

Novartis announced that Hervé Hoppenot, President of Novartis Oncology, will leave Novartis with immediate effect…

Novartis logo

Novartis to highlight long-term data, innovative pipeline for patients with hematologic diseases and breast cancer at ASH and SABCS

Industry news / 4 December 2013 / Novartis

“Cancer treatment has been revolutionized by targeted therapies, which have established a highly successful approach to the management of many cancers…”

Novartis logo

Novartis breakthrough therapy LDK378 shows a marked clinical response in patients with ALK+ non-small cell lung cancer

Industry news, News / 3 June 2013 / Novartis

Novartis announced data on its investigational compound LDK378…

Novartis logo
Novartis logo
Novartis logo
Novartis logo
Novartis logo
Novartis logo

Novartis drug Exjade® recommended by CHMP for EU approval

Industry news, News / 16 November 2012 / Novartis

The CHMP of the EMA adopted a positive opinion for Exjade®…

Novartis logo

Novartis drug Signifor® recommended by FDA advisory committee for approval to treat patients with Cushing’s disease

Industry news, News / 7 November 2012 / Novartis

Committee votes unanimously in favor of Signifor (pasireotide)…

Novartis logo


Webinar: Understanding ISO Standards: ISO 14644-2:2015 Cleanroom MonitoringWATCH NOW
+ +